Long-term Metazym Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Shire
ClinicalTrials.gov Identifier:
NCT00633139
First received: February 29, 2008
Last updated: July 14, 2015
Last verified: February 2014
Results First Received: October 6, 2010  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Late Infantile Metachromatic Leukodystrophy
Intervention: Biological: Recombinant human Arylsulfatase A (rhASA)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Children with an established diagnosis of late metachromatic leukodystrophy (MLD) due to arylsulfatase A (ASA) deficiency were recruited.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
All participants that completed study recombinant human arylsulfatase A (rhASA-01) (NCT00418561) except 1 participant who did not complete (at week 18) the rhASA-01 (NCT00418561) participated in HGT-MLD-048/rhASA-03 (NCT00633139).

Reporting Groups
  Description
Cohort 1 Participants received a single dose of rhASA at 25 units per kilogram (U/kg) intravenous (IV) infusion in rhASA-01 (NCT00418561) study. Thereafter a repeated dose of rhASA at 50 U/kg, over 30 minutes was administered every other week up to Week 52.
Cohort 2 Participants received a repeated dose of rhASA at 100 U/kg IV infusion over 30 minutes was administered every other week up to Week 52.
Cohort 3 Participants received a repeated dose of rhASA at 200 U/kg IV infusion over 60 minutes was administered every other week up to Week 52.

Participant Flow:   Overall Study
    Cohort 1     Cohort 2     Cohort 3  
STARTED     4     5     4  
COMPLETED     4     4     3  
NOT COMPLETED     0     1     1  
Non compliance                 0                 0                 1  
Withdrawal by Subject                 0                 1                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Cohort 1 Participants received a single dose of rhASA at 25 U/kg IV infusion in rhASA-01 (NCT00418561) study. Thereafter a repeated dose of rhASA at 50 U/kg, over 30 minutes was administered every other week up to Week 52.
Cohort 2 Participants received a repeated dose of rhASA at 100 U/kg IV infusion over 30 minutes was administered every other week up to Week 52.
Cohort 3 Participants received a repeated dose of rhASA at 200 U/kg IV infusion over 60 minutes was administered every other week up to Week 52.
Total Total of all reporting groups

Baseline Measures
    Cohort 1     Cohort 2     Cohort 3     Total  
Number of Participants  
[units: participants]
  4     5     4     13  
Age  
[units: participants]
       
<=18 years     4     5     4     13  
Between 18 and 65 years     0     0     0     0  
>=65 years     0     0     0     0  
Age  
[units: months]
Mean (Standard Deviation)
  36.25  (9.32)     41.80  (10.13)     30.75  (7.27)     36.69  (9.59)  
Gender  
[units: participants]
       
Female     2     3     3     8  
Male     2     2     1     5  
Region of Enrollment  
[units: participants]
       
Denmark     4     5     4     13  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Relative Changes (%) in Gross Motor Function Measurement (GMFM)   [ Time Frame: Baseline, 52 Weeks ]

2.  Primary:   Relative Change in Mullen's Scales of Early Learning   [ Time Frame: Baseline, 52 Weeks ]

3.  Secondary:   Change in Cerebrospinal Fluid (CSF) Sulfatide   [ Time Frame: Baseline, 52 Weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Norman Barton
Organization: Shire Human Genetic Therapies, Inc
phone: 781-482-9297
e-mail: nbarton@shire.com


No publications provided


Responsible Party: Shire
ClinicalTrials.gov Identifier: NCT00633139     History of Changes
Other Study ID Numbers: HGT-MLD-048, 2007-006345-40, 2006-005341-11
Study First Received: February 29, 2008
Results First Received: October 6, 2010
Last Updated: July 14, 2015
Health Authority: Denmark: Danish Dataprotection Agency
Denmark: Danish Medicines Agency
Denmark: Ethics Committee